Press Release
Dr. Kirstin Henze Leica Microsystems GmbH
Tel. +49 (0)6441/29-2550 Ernst-Leitz-Straße 17-37
Fax +49 (0)6441/29-2527 DE-35578 Wetzlar
www.leica-microsystems.com
Press Release
May 31, 2011
Protecting Patient Safety
Innovative Sample Tracking System from Leica Microsystems
Leica Microsystems today announced the release of Leica CEREBRO, an important new system for tracking patient specimens in histopathology laboratories. The system positively tracks patient samples, from admittance to archive, reducing the risk of laboratory errors and possible misdiagnosis while improving workflow efficiency.
Primarily used in laboratories testing human tissue as part of cancer diagnosis, Leica CEREBRO ensures that the correct patient tissue is positively identified through all critical steps required to prepare tissue for diagnosis. Further, Leica CEREBRO also tracks all patient specimens to ensure they undergo the correct preparation as requested by the diagnosing pathologist.
According to Arnd Kaldowski, President of Leica Microsystems’ Biosystems Division, “Patient care is of utmost concern, and we’ve developed Leica CEREBRO so laboratories can have a system that eliminates the sort of mix-ups that could lead to misdiagnosis and potentially tragic patient outcomes. With this system we are providing an extra level of care so that physicians and patients can be confident they are getting the right diagnosis leading to the correct treatment”.
Leica CEREBRO works by labeling test request forms and the containers, cassettes and slides that hold patient tissue with the correct unique identifier for each patient. Then, at critical stages of the histology process, that identification, along with the required process, is scanned and positively confirmed to create full accountability for each step performed. This means the potential for human error is greatly reduced and those that do occur are quickly detected and immediately corrected.
Part of Leica Microsystems’ Total Histology solutions, Leica CEREBRO joins a complete range of histology systems. It is available immediately in North America, the United Kingdom, Australia and New Zealand. It will be released in additional European countries later in 2011 and in more countries and regions throughout 2012.
______
Leica Microsystems is a world leader in microscopes and scientific instruments. Founded as a family business in the nineteenth century, the company’s history was marked by unparalleled innovation on its way to becoming a global enterprise.
Its historically close cooperation with the scientific community is the key to Leica Microsystems’ tradition of innovation, which draws on users’ ideas and creates solutions tailored to their requirements. At the global level, Leica Microsystems is organized in four divisions, all of which are among the leaders in their respective fields: the Life Science Division, Industry Division, Biosystems Division and Medical Division.
Leica Microsystems’ Biosystems Division, also known as Leica Biosystems, offers histopathology laboratories the most extensive product range with appropriate products for each work step in histology and for a high level of productivity in the working processes of the entire laboratory.
The company is represented in over 100 countries with 12 manufacturing facilities in 7 countries, sales and service organizations in 19 countries and an international network of dealers. The company is headquartered in Wetzlar, Germany.
2 / 2